2-acetylamino-3-mercaptopropionic acid ethyl ester | 223594-28-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-acetylamino-3-mercaptopropionic acid ethyl ester
• 英文别名: N-Acetylcysteinethylester；HCys(OEt)(NAc)；N-acetylcysteine ethyl ester；ethyl acetyl-L-cysteinate；ethyl 2-acetamido-3-sulfanylpropanoate
• CAS: 223594-28-3
• 化学式: C₇H₁₃NO₃S
• 分子量: 191.251
• InChiKey: MSMRAGNKRYVTCX-UHFFFAOYSA-N

物化性质

• 沸点：
  337.6±32.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-acetylamino-3-mercaptopropionic acid ethyl ester 在 三乙烯二胺 、 硫酸 作用下， 以 乙醇 、 水 、 二甲基亚砜 为溶剂， 生成 Ethyl-5-(3,5-di-tert-butyl-4-hydroxyphenyl)-6-hydroxy-3H-naphtho[2,1-b][1,4]thiazin-2-carboxylat
  参考文献：
  名称：

  Richwien; Wurm, Gotthard, Pharmazie, 2004, vol. 59, # 12, p. 906 - 912

  摘要：

  DOI：
• 作为产物：
  描述：

  乙醇 、 N-乙酰基-L-半胱氨酸 在 乙酰溴 作用下， 反应 24.0h， 生成 2-acetylamino-3-mercaptopropionic acid ethyl ester 、
  参考文献：
  名称：

  Acetyl Bromide-Alcohols as Convenient Reaction Systems for: a) Removal ofN-tert-Boc,N-Cbz AndN-Ac Protective Groups, b) Esterifications and Transesterifications, c) Debenzylation of Aryl-O-Benzyl Ethers

  摘要：

  Hydrogen bromide generated in situ by the addition of acetyl bromide to alcohols is a useful reagent for esterifications and transesterifications; N-tert-Boc, N-Cbz and N-Ac deprotections; and debenzylation reactions.

  DOI：

  10.1080/00397919908086117

文献信息

• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• Combination Therapies for Treating Metabolic Disorders
  申请人：Mayoux Eric

  公开号：US20100239552A1

  公开（公告）日：2010-09-23

  This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.

  本发明涉及包含抗氧化剂、抗炎剂和可选地至少一种其他抗糖尿病药物的药物组合，用于治疗代谢紊乱。本发明还包括包含抗氧化剂、抗炎剂、可选地至少一种其他抗糖尿病药物和至少一种药用载体的药用可接受的组合物。本发明的这些组合和组合物作为治疗代谢紊乱的方法是有用的，包括糖尿病，特别是I型和II型糖尿病，以及与糖尿病相关的疾病和紊乱，包括但不限于动脉粥样硬化、心血管疾病、炎症性疾病、肾病、神经病、视网膜病变、β细胞功能障碍、血脂异常、LADA、代谢综合征、高血糖、胰岛素抵抗和/或慢性阻塞性肺疾病在哺乳动物，特别是糖尿病哺乳动物，特别是人类患者中。本发明特别涉及包含硫辛酸、来自二氟尼索、双氯芬酸、右布洛芬、右侧氧布洛芬、萘普生和水杨酸的一种或多种抗炎药物以及可选地一种或多种药用可接受的载体的药物组合。本发明的组合物作为治疗代谢紊乱的方法是有用的，包括II型糖尿病、胰岛素抵抗、β细胞功能障碍和高血糖在患者，特别是糖尿病患者中。
• Zinc−Thiolate Complexes of the Bis(pyrazolyl)(thioimidazolyl)hydroborate Tripods for the Modeling of Thiolate Alkylating Enzymes
  作者：Mian Ji、Boumahdi Benkmil、Heinrich Vahrenkamp

  DOI：10.1021/ic0484147

  日期：2005.5.1

  -thioimidazol-1-yl)hydroborate (L(2)), together with zinc nitrate or zinc chloride and the corresponding thiolates, have yielded a total of 17 zinc-thiolate complexes. These comprise aliphatic as well as aromatic thiolates and a cysteine derivative. Structure determinations have confirmed the tetrahedral ZnN(2)S(2) coordination in the complexes. Upon reaction with methyl iodide, the species L(1).Zn-SR

  新的三脚架配体双（吡唑基）（3-叔丁基-2-硫代咪唑-1-基）氢硼酸酯（L（1））和双（吡唑基）（3-异丙基-2-硫代咪唑-1-基）氢硼酸酯（ L（2））与硝酸锌或氯化锌以及相应的硫醇盐一起，共产生了17种硫醇锌络合物。这些包括脂族以及芳族硫醇盐和半胱氨酸衍生物。结构确定已确认复合物中的四面体ZnN（2）S（2）配位。与甲基碘反应后，物质L（1）.Zn-SR缓慢转化为L（1）.Zn-1和游离硫醚CH（3）SR。动力学分析表明这些烷基化比三（吡唑基）硼酸酯配合物Tp（Ph，Me）Zn-SR慢约1个数量级。发现即使在80°C的DMSO中，用磷酸三甲酯进行的烷基化反应也进行得非常缓慢。
• [EN] N-ACETYL L-CYSTEINE CHELATES AND METHODS FOR MAKING AND USING THE SAME<br/>[FR] CHÉLATES DE N-ACÉTYLE L-CYSTÉINE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：VIVA PHARMACEUTICAL INC

  公开号：WO2014209412A1

  公开（公告）日：2014-12-31

  A nutritional supplement for a human, the supplement having a chelate comprised of an N-acetyl-L-cysteine ligand bonded to a metal to form a chelate ring. A method for preparing a chelate comprised of N-acetyl-L-cysteine ligand and a metal having the steps of: dissolving an amount of N-acetyl-L-cysteine in an aqueous solution, adding a metal to the aqueous solution, stirring and heating the aqueous solution, and removing the solvent under reduced pressure. A method of treating a human for one or more of oxidative stress, cardiovascular disease, cerebrovascular disease, neurodegenerative diseases, Alzheimer's disease, ADHD, bipolar, schizophrenia, autism, dementia, and HIV in a human comprising administering an effective amount of a composition having N-acetyl-L-cysteine in a chelate formation with a metal. A compound having a chelate formulation with a metal being chelated by an N-acetyl-L-cysteine ligand.

  一种用于人类的营养补充剂，该补充剂具有一个螯合物，由N-乙酰-L-半胱氨酸配体与金属结合形成一个螯合环。一种制备由N-乙酰-L-半胱氨酸配体和金属组成的螯合物的方法包括以下步骤：在水溶液中溶解一定量的N-乙酰-L-半胱氨酸，向水溶液中加入金属，搅拌和加热水溶液，然后在减压下去除溶剂。一种治疗人类氧化应激、心血管疾病、脑血管疾病、神经退行性疾病、阿尔茨海默病、注意力缺陷多动障碍、躁郁症、精神分裂症、自闭症、痴呆症和艾滋病等的方法，包括向人类施用含有N-乙酰-L-半胱氨酸与金属形成螯合物的有效量的组合物。一种具有金属与N-乙酰-L-半胱氨酸配体螯合的螯合制剂的化合物。
• Propionic acids, propionic acid esters, and related compounds
  申请人：Promentis Pharmaceuticals, Inc.

  公开号：US09193681B1

  公开（公告）日：2015-11-24

  The invention relates to compounds of the following formula: and their pharmaceutically acceptable salts, pharmaceutical compositions containing this compounds, and methods of using this compound for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

  本发明涉及以下式的化合物及其药学上可接受的盐，含有该化合物的制药组合物以及使用该化合物治疗各种疾病或病况的方法，包括但不限于中枢神经系统（CNS）相关的疾病和/或病况，包括精神分裂症，肾上腺白质脑病，线粒体疾病（如 Leigh 综合征、Alpers 病和 MELAS），亨廷顿病，拔毛癖，HIV 相关神经认知障碍，缺氧缺血性脑病，药物渴求和药物成瘾。